Navigation Links
New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
Date:5/17/2012

WASHINGTON, May 17, 2012 /PRNewswire-USNewswire/ -- Despite increasing budget pressures, countries around the world are making substantial investments in pro-innovation policies and programs to lure the biopharmaceutical research sector away from the U.S., finds a new study released by Battelle Technology Partnership Practice.

The study, commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA), further found that while many countries are cutting public expenditures, they are continuing to expand research and development incentives to attract and grow their biopharmaceutical company presence. Despite the short-term costs associated with these investments, foreign governments recognize the long-term economic benefits.

"In countries around the world, governments clearly recognize the potential benefit that biopharmaceutical research companies offer in terms of economic contributions and job growth – especially in a time when economic growth is so fundamentally needed," said PhRMA President and CEO John J. Castellani. "If the U.S. doesn't take similar pro-innovation policy steps to counter these efforts – such as reauthorization of the Prescription Drug User Fee Act, progress on the Trans-Pacific Partnership, intellectual property incentives such as 12 years of data protection for innovator biologics, and a permanent R&D tax credit – our global leadership in medical innovation is at risk."

A U.S. policy framework to help counter these efforts would provide regulatory certainty, ensure patient choice and access to medicines, and incentivize future research and development, he explained.   

Battelle's report focused on 18 countries and the European Union. These countries were selected because of their interest in growing an innovation economy through pro-innovation policies and programs that can be applied to R&D-intensive sectors such as the biopharmaceutical industry.

For example, other countries are increasingly seeking to make substantial public investments in R&D infrastructure, fostering R&D investment via tax and other research incentives, focusing on attracting and growing talent in related employment fields, ensuring access to capital and fostering public-private partnerships.

In addition, many countries have their own national innovation agenda specifically focusing on biomedical research.

Countries selected include a mix of developed countries with existing biopharmaceutical presence (Australia, Canada, France, Germany, Ireland, Israel, Italy, Japan, Sweden, the United Kingdom, and the EU) and emerging countries that are targeting the sector for new growth (Brazil, Chile, China, Russia, Saudi Arabia, Singapore, South Africa and South Korea).

"Until the early 1990s, Germany was known as 'the world's medicine cabinet,'" said Castellani. "Unless we take steps to support innovative industries at a national level, we too will lose our standing, and with it, our jobs. Without a national biomedical innovation agenda, we're not pitting America up against other countries – we're pitting our states up against like-minded foreign governments. So states with vibrant biopharmaceutical research clusters, like North Carolina and Massachusetts, aren't just competing with each other. They're competing with countries like Singapore."  

In the U.S., the biopharmaceutical sector is a large contributor to our economic landscape, with more than 650,000 direct jobs (supporting a total of nearly 4 million jobs) and an economic output that totals more than $900 billion. Also, the sector accounts for nearly 20 percent of all research and development investment by businesses in America. The impact of the sector goes beyond jobs – over the last decade, biopharmaceutical companies have brought more than 300 new medicines to the patients who need them.

The full report can be found here.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $49.5 billion in 2011 in discovering and developing new medicines.

Find PhRMA Online:

For information on how innovative medicines save lives, visit: http://www.innovation.org

For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org

For information on ensuring the flow of medicines during public health emergencies, visit http://www.rxresponse.org


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 25,2016 FDA 510(k) clearance ... platform for urological and surgical applications ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) ... the US with the 12 th 510(k) ... (FDA). This new FDA clearance covers Confocal Miniprobes ...
(Date:5/25/2016)... , May 25, 2016 ... Market by Type (3D, 2D, 4D), by Therapeutic Area ... by End User (Medical Device Manufacturers, Hospitals/ Clinics) - ... the global Medical Animation Market for the forecast period ... reach USD 301.3 Million by 2021 from USD 117.3 ...
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient dringenden ... Brustkrebs   QIAGEN N.V. (NASDAQ: ... heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis ... für die Onkologie eingegangen zu sein. Ein erstes ...
Breaking Medicine Technology:
(Date:5/26/2016)... Diego, CA (PRWEB) , ... May 26, 2016 , ... ... with him running plumbing calls throughout the beach community. His vision to grow the ... affordable rates and ensuring they maintain the highest level of training and customer service. ...
(Date:5/26/2016)... Overland Park, KS (PRWEB) , ... May 26, ... ... to Hypercet, an industry leader in Blood Pressure products . , High ... to mitigate its effects. Left untreated, high blood pressure can lead to heart ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie is a great ... yourself and save. For a limited time only (offer expires May 31, 2016) customers ... than one, by using the promo code "Memorial" at checkout. The more Bunion Booties ...
(Date:5/25/2016)... ... May 25, 2016 , ... “We ... Managing Partner at HealthScape Advisors. “Brad brings significant experience advising healthcare provider clients ... system accelerates with the implementation of MACRA, we believe that continuing to add ...
(Date:5/25/2016)... ... May 25, 2016 , ... Serenity ... produced another video highlighting one of the many supplemental program options offered at ... Taylor, a 5 th Degree Black Belt in the Shorin-ryu style of Karate ...
Breaking Medicine News(10 mins):